COMMUNIQUÉ DE PRESSE publié le 13/02/2023 à 08:00, il y a 3 années 4 mois Press release: KPN nominates Herman Dijkhuizen to Supervisory Board
COMMUNIQUÉ DE PRESSE publié le 31/01/2023 à 07:29, il y a 3 années 5 mois Q4 2022 Press Release: KPN delivers on FY 2022 outlook with sustainable Group service revenue growth
COMMUNIQUÉ DE PRESSE publié le 17/01/2023 à 08:00, il y a 3 années 5 mois Press Release: KPN nominates Frank Heemskerk to Supervisory Board and proposes to reappoint Jolande Sap
COMMUNIQUÉ DE PRESSE publié le 24/11/2020 à 13:00, il y a 5 années 7 mois Royal KPN N.V. Press Release: Members of Board of Management buy KPN shares
Publié le 09/07/2026 à 13:56, il y a 26 minutes Statement of transactions in own shares from July 6, 2026 to July 8, 2026
Publié le 09/07/2026 à 13:56, il y a 26 minutes Déclaration des transactions sur actions propres réalisées du 06/07/2026 au 08/07/2026
Publié le 09/07/2026 à 07:30, il y a 6 heures 53 minutes Half-year liquidity contract statement June 30, 2026
Publié le 09/07/2026 à 07:30, il y a 6 heures 53 minutes Half-year liquidity contract statement June 30, 2026
Publié le 09/07/2026 à 14:00, il y a 23 minutes GameSquare Signs Dairy MAX as Brand Partner for the World of Dance
Publié le 09/07/2026 à 14:00, il y a 23 minutes Horizon Aircraft Selects BETA Technologies Advanced Flight Control Computers and Software for the Cavorite X7
Publié le 09/07/2026 à 14:00, il y a 23 minutes Loop Industries Announces Date for First Quarter Fiscal 2027 Financial Results and Conference Call
Publié le 09/07/2026 à 14:05, il y a 17 minutes DJI Puts Drones to the Test on the World's Highest Peak, Advancing Critical High-Altitude Delivery, Mapping, and Climate Research Applications
Publié le 09/07/2026 à 12:35, il y a 1 heure 47 minutes Cognizant to scale to 5,000 Frontier Certified Engineers and 10,000 Frontier Business Operators
Publié le 09/07/2026 à 12:30, il y a 1 heure 53 minutes Immunic to Participate in Investor Conferences in July
Publié le 09/07/2026 à 12:16, il y a 2 heures 6 minutes Phase III GRAPPA trial supports ATLG (Grafalon®) as standard of care in matched unrelated donor stem cell transplantation
